Ebola cases are rising in Congo and Uganda, prompting vaccine developers to accelerate work on the rare Bundibugyo strain. IAVI CEO Mark Feinberg said a vaccine candidate could enter human trials by year-end. The development is important medically but is unlikely to move broader markets materially.
Ebola cases are rising in Congo and Uganda, prompting vaccine developers to accelerate work on the rare Bundibugyo strain. IAVI CEO Mark Feinberg said a vaccine candidate could enter human trials by year-end. The development is important medically but is unlikely to move broader markets materially.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.20
